• Prolactin and breast disease: new data

Prolactin and breast disease: new data

HEALTH OF WOMAN. 2018.8(134):14–17

Zhuk S. I.
Department of Obstetrics, Gynecology and Fetal Medicine of the National Medical Academy of Postgraduate Education named after PL Shupika, Kyiv

Published: Female doctor № 5 (73) / 2017

Functions and role of prolactin in a woman’s body, new data on the pathological role of prolactin in the genesis of breast cancer development. The medical strategies aimed at reducing the level of this hormone are outlined.

Key words: prolactin, hyperprolactinemia, breast cancer.

REFERENCES

1. World cancer report 2014. (2014). Geneva, WHO: 630.

2. Biuleten Natsionalnoho kantser-reiestru № 18 – «Rak v Ukraini, 2015-2016»

3. Bespalov VG, Travina ML. (2015). Fibrozno-kistoznaya bolezn i risk raka molochnoy zhelezy (obzor literatury). Opuholi zhenskoy reproduktivnoy sistemy 11;4:58–70.

4. Grattan DR. (2014). 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J. Endocrinol. 226;2:t101–t122. https://doi.org/10.1530/JOE-15-0213; PMid:26101377 PMCid:PMC4515538

5. Grattan DR. (2015). 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J. Endocrinol. 226;2:101–122. https://doi.org/10.1530/JOE-15-0213; PMid:26101377 PMCid:PMC4515538

6. Rozhkova NI, Podzolkova NM, Ovsyannikova T. (2016). O roli prolaktina v geneze zabolevaniy molochnyih zhelez. Status Praesens 4 (33).

7. Meczekalski B, Katulski K, Podfigurna-Stopa A et al. (2016). Spontaneous endogenous pulsatile release of kisspeptin is temporally coupled with luteinizing hormone in healthy women. Fertil. Steril. 105;5:1345–1350. https://doi.org/10.1016/j.fertnstert.2016.01.029; PMid:26859129

8. Kuznetsova IV, Hovrina EA, Kirpikov AS. (2012). Vosstanovlenie fertilnosti u zhenschin s genitalnyim endometriozom. Akusherstvo i ginekologiya 2:10–15.

9. Tworoger SS, Eliassen AH, Zhang X et al. (2013). A 20- year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73;15:4810–4819. https://doi.org/10.1158/0008-5472.CAN-13-0665; PMid:23783576 PMCid:PMC3738582

10. Semimilliardnyiy zhitel Zemli rodilsya v Rossii. URL: http://www.ntv.ru/novosti/243552.

11. Bernichtein S, Touraine P, Goffin V. (2010). New concepts in prolactin biology. J. Endocrinol. 206;1:1–11. https://doi.org/10.1677/JOE-10-0069; PMid:20371569

12. Tworoger SS, Hankinson SE. (2008). Prolactin and breast cancer etiology: An epidemiologic perspective. J. Mammary Gland Biol. Neoplasia 13;1:41–53. https://doi.org/10.1007/s10911-008-9063-y; PMid:18246319

13. Berinder K, Akre O, Granath F et al. (2011). Cancer risk in hyperprolactinemia patients: A population-based cohort study. Eur. J. Endocrinol. 165;2:209–215. https://doi.org/10.1530/EJE-11-0076; PMid:21602317

14. McHale K, Tomaszewski JE, Puthiyaveettil R et al. (2008). Altered expression of prolactin receptorassociated signaling proteins in human breast carcinoma. Mod. Pathol. 21;5:565–571. https://doi.org/10.1038/modpathol.2008.7; PMid:18246042

15. Nilsson J, Bjursell G, Kannius-Janson M. (2006). Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol. Cell Biol. 26;15:5663–5674. https://doi.org/10.1128/MCB.02095-05; PMid:16847321 PMCid:PMC1592781

16. Garcia RM, Zamarripa DA, Arnold E et al. (2016). Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine 7:35–49. https://doi.org/10.1016/j.ebiom.2016.03.048; PMid:27322457 PMCid:PMC4909382

17. Radzinskiy VE, Ordiyants IM. (2013). Vozmozhnosti terapii sochetaniya miomyi matki i dobrokachestvennyih displaziy molochnyih zhelez. Akusherstvo i ginekologiya 4:44–47.

18. Elakad EV i dr. (2011). Sostoyanie gormonalnoy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat i ditya 1:342–346.

19. Van Die MD, Burger HG, Teede HJ et al. (2013). Vitex agnus-castus extracts for female reproductive disorders: A systematic review of clinical trials. Planta Med. 79;7:562–575. PMid:23136064

20. Rapkin AJ, Lewis EI. (2013). Treatment of premenstrual dysphoric disorder. Womens Health (Lond.) 9;6:537–556. https://doi.org/10.2217/WHE.13.62; PMid:24161307

21. Halaska M, Beles P, Gorkow C et al. (1999). Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: Results of a placebocon­trolled double-blind study. Breast. 8;4:175–181. https://doi.org/10.1054/brst.1999.0039; PMid:14731436

22. Wuttke W, Splitt G, Gorkow C et al. (1997). Treatment of cyclical mastalgia with a medicinal product containing agnus castus: Results of a randomized, placebo-controlled, double blind study. Geburtsh. u. Frauenheilk. 57:569–574. https://doi.org/10.1055/s-2007-1023139

23. Sotnikova LS i dr. (2011). Sostoyanie gormonalnoy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat i ditya 1:342–346.

24. Radzinskiy VE i dr. (2016). Molochnyie zhelezyi i ginekologicheskie zabolevaniya: ot obschnosti patogeneticheskih vozzreniy k prakticheskim resheniyam. Reproduktivnaya endokrinologiya 2.

Confirm the action on the portal med-expert.com.ua:

The information is intended only for healthcare professionals, persons with higher or secondary specialized medical education. Confirm that you are a specialist in the field of healthcare and are familiar with the user agreement.